Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow

The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.

Relonova is manufactured at the capacities of the Technological Center NovaMedica Innotech (100% subsidiary of NovaMedica, portfolio company of RusNano) and located in Technopolis Moscow. To date, the facility has produced more than 140 thousand packs of the new drug, which is released in the form of 10mg tablets. Relonova was launched in the market on July 7 and will be available for purchase in pharmacies and for ordering as early as this month.

According to the IQVIA analytical agency, in 2022, the volume of the Russian market of drugs for the treatment of migraine amounted to about 2 billion rubles, which is 24% more than in the previous year.

Source